MRNS
Marinus Pharmaceuticals, Inc. [MRNS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
MRNS Stock Summary
Top 10 Correlated ETFs
MRNS
Top 10 Correlated Stocks
MRNS
In the News
MRNS Financial details
Company Rating
Neutral
Market Cap
410.91M
Income
-141.25M
Revenue
30.99M
Book val./share
0.3
Cash/share
2.65
Dividend
-
Dividend %
-
Employees
165
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-4.43
Forward P/E
-
PEG
-0.11
P/S
19.37
P/B
10.87
P/C
0.54
P/FCF
-5.3
Quick Ratio
5.91
Current Ratio
6.38
Debt / Equity
6.54
LT Debt / Equity
5.68
-
-
EPS (TTM)
-2.63
EPS next Y
-
EPS next Q
-
EPS this Y
415.69%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-2.02%
EPS Q/Q
21.31%
-
-
-
-
SMA20
-36.56%
SMA50
-42.28%
SMA100
-6.34%
Inst Own
72.6%
Inst Trans
0.84%
ROA
-67%
ROE
-171%
ROC
-0.74%
Gross Margin
96%
Oper. Margin
-405%
Profit Margin
-432%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
5.57-11.26
52W High
-86.91%
52W Low
-71.2%
RSI
13.62
Rel Volume
20.85
Avg Volume
440.93K
Volume
9.19M
Perf Week
-82.44%
Perf Month
-84.42%
Perf Quarter
-78.57%
Perf Half Y
-78.82%
-
-
-
-
Beta
0.888
-
-
Volatility
3.31%, 2.27%
Prev Close
20%
Price
1.44
Change
9.09%
MRNS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0.06 | 0.42 | 0.65 | 0.58 | |
| Net income per share | -3.95 | -2.44 | -2.77 | -0.51 | -2.63 | |
| Operating cash flow per share | -3.57 | -2.23 | -1.51 | -2.89 | -2.2 | |
| Free cash flow per share | -3.6 | -2.23 | -1.59 | -2.93 | -2.2 | |
| Cash per share | 6.73 | 5.13 | 3.35 | 6.16 | 2.8 | |
| Book value per share | 6.44 | 5.03 | 1.46 | 2.97 | 0.31 | |
| Tangible book value per share | 6.44 | 5.03 | 1.46 | 2.97 | 0.31 | |
| Share holders equity per share | 6.44 | 5.03 | 1.46 | 2.97 | 0.31 | |
| Interest debt per share | 0.03 | 0.11 | 1.2 | 2.13 | 2.36 | |
| Market cap | 117.75M | 332.69M | 435.96M | 155.51M | 584.22M | |
| Enterprise value | 27.25M | 194.7M | 353.84M | -12.37M | 574.01M | |
| P/E ratio | -2.19 | -4.99 | -4.29 | -7.85 | -4.13 | |
| Price to sales ratio | 0 | 193.65 | 28.41 | 6.1 | 18.85 | |
| POCF ratio | -2.42 | -5.46 | -7.86 | -1.38 | -4.95 | |
| PFCF ratio | -2.4 | -5.46 | -7.47 | -1.36 | -4.95 | |
| P/B Ratio | 1.34 | 2.42 | 8.15 | 1.34 | 34.85 | |
| PTB ratio | 1.34 | 2.42 | 8.15 | 1.34 | 34.85 | |
| EV to sales | 0 | 113.33 | 23.06 | -0.49 | 18.52 | |
| Enterprise value over EBITDA | -0.5 | -2.87 | -3.68 | 2.15 | -4.38 | |
| EV to operating cash flow | -0.56 | -3.2 | -6.38 | 0.11 | -4.86 | |
| EV to free cash flow | -0.56 | -3.2 | -6.06 | 0.11 | -4.86 | |
| Earnings yield | -0.46 | -0.2 | -0.23 | -0.13 | -0.24 | |
| Free cash flow yield | -0.42 | -0.18 | -0.13 | -0.74 | -0.2 | |
| Debt to equity | 0.01 | 0.02 | 0.77 | 0.63 | 6.54 | |
| Debt to assets | 0 | 0.02 | 0.3 | 0.28 | 0.64 | |
| Net debt to EBITDA | 1.67 | 2.03 | 0.85 | 29.17 | 0.08 | |
| Current ratio | 11.72 | 13.06 | 3.03 | 4.38 | 4.07 | |
| Interest coverage | 0 | 0 | -37.54 | -10.57 | -7.78 | |
| Income quality | 0.9 | 0.9 | 0.56 | 5.7 | 0.83 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 10.8 | 2.43 | 0 | 0 | |
| Research and developement to revenue | 0 | 29.75 | 4.79 | 3.14 | 3.19 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0 | 0.05 | 0.02 | 0 | |
| Capex to revenue | 0 | 0 | -0.19 | -0.07 | 0 | |
| Capex to depreciation | -1.4 | 0 | -8.14 | -4.24 | -0.22 | |
| Stock based compensation to revenue | 0 | 4.45 | 0.9 | 0.58 | 0.5 | |
| Graham number | 23.91 | 16.63 | 9.53 | 5.82 | 4.3 | |
| ROIC | -0.61 | -0.48 | -1.02 | -0.71 | -1.02 | |
| Return on tangible assets | -0.54 | -0.44 | -0.74 | -0.08 | -0.83 | |
| Graham Net | 5.91 | 4.58 | 1.02 | 2.61 | 0 | |
| Working capital | 86.1M | 129.43M | 82.36M | 185.68M | 124.62M | |
| Tangible asset value | 87.77M | 137.2M | 53.49M | 116M | 16.77M | |
| Net current asset value | 83.06M | 126.89M | 39.57M | 97.03M | 11.1M | |
| Invested capital | 0.01 | 0.02 | 0.77 | 0.63 | 6.54 | |
| Average receivables | 0 | 823K | 2.42M | 4.77M | 5.07M | |
| Average payables | 2.62M | 2.49M | 2.67M | 4.73M | 5.17M | |
| Average inventory | 0 | -3.14M | -7.8M | -4.62M | 1.25M | |
| Days sales outstanding | 0 | 349.7 | 75.78 | 90.94 | 44.75 | |
| Days payables outstanding | 2K | 15.98 | 771.98 | 6.81K | 587.97 | |
| Days of inventory on hand | 0 | -45.41 | -2.3K | 82.66 | 354.42 | |
| Receivables turnover | 0 | 1.04 | 4.82 | 4.01 | 8.16 | |
| Payables turnover | 0.18 | 22.84 | 0.47 | 0.05 | 0.62 | |
| Inventory turnover | 0 | -8.04 | -0.16 | 4.42 | 1.03 | |
| ROE | -0.61 | -0.49 | -1.9 | -0.17 | -8.43 | |
| Capex per share | -0.03 | 0 | -0.08 | -0.05 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.16 | 0.2 | 0.12 | 0.14 | 0.13 | |
| Net income per share | -0.76 | -0.67 | -0.61 | -0.61 | -0.74 | |
| Operating cash flow per share | -0.49 | -0.8 | -0.46 | -0.47 | -0.48 | |
| Free cash flow per share | -0.49 | -0.8 | -0.46 | -0.47 | -0.48 | |
| Cash per share | 5.35 | 3.85 | 3.34 | 3.27 | 2.65 | |
| Book value per share | 2.58 | 1.64 | 1.09 | 1.01 | 0.3 | |
| Tangible book value per share | 2.58 | 1.64 | 1.09 | 1.01 | 0.3 | |
| Share holders equity per share | 2.58 | 1.64 | 1.09 | 1.01 | 0.3 | |
| Interest debt per share | 1.7 | 2.1 | 2.09 | 1.3 | 2.01 | |
| Market cap | 178.99M | 357.21M | 570.71M | 434.06M | 616.2M | |
| Enterprise value | 11.12M | 312.7M | 548.7M | 367.78M | 605.99M | |
| P/E ratio | -1.3 | -2.58 | -4.47 | -3.29 | -3.69 | |
| Price to sales ratio | 24.99 | 34.41 | 93.85 | 59.15 | 85.7 | |
| POCF ratio | -8.17 | -8.61 | -23.43 | -17.24 | -22.83 | |
| PFCF ratio | -8.13 | -8.61 | -23.43 | -17.18 | -22.8 | |
| P/B Ratio | 1.54 | 4.2 | 9.95 | 7.96 | 36.76 | |
| PTB ratio | 1.54 | 4.2 | 9.95 | 7.96 | 36.76 | |
| EV to sales | 1.55 | 30.13 | 90.23 | 50.12 | 84.28 | |
| Enterprise value over EBITDA | -0.38 | -10.22 | -18.83 | -11.62 | -17.16 | |
| EV to operating cash flow | -0.51 | -7.54 | -22.53 | -14.61 | -22.45 | |
| EV to free cash flow | -0.51 | -7.54 | -22.53 | -14.56 | -22.42 | |
| Earnings yield | -0.19 | -0.1 | -0.06 | -0.08 | -0.07 | |
| Free cash flow yield | -0.12 | -0.12 | -0.04 | -0.06 | -0.04 | |
| Debt to equity | 0.63 | 1.23 | 1.84 | 1.36 | 6.54 | |
| Debt to assets | 0.28 | 0.46 | 0.53 | 0.37 | 0.64 | |
| Net debt to EBITDA | 5.79 | 1.46 | 0.76 | 2.09 | 0.29 | |
| Current ratio | 4.38 | 9.26 | 7.6 | 6.38 | 4.07 | |
| Interest coverage | -7.92 | -7.95 | -7.47 | 7.46 | -8.24 | |
| Income quality | 0.64 | 1.19 | 0.76 | 0.76 | 0.65 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 6.05 | 0 | 2.59 | 0 | 0 | |
| Research and developement to revenue | 2.99 | 2.69 | 3.52 | 3.22 | 3.65 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.01 | 0 | 0 | -0.01 | 0 | |
| Capex to depreciation | -1.12 | 0 | 0 | -0.6 | -0.27 | |
| Stock based compensation to revenue | 0.53 | 0.36 | 0.64 | 0.55 | 0.55 | |
| Graham number | 6.65 | 4.97 | 3.86 | 3.73 | 2.21 | |
| ROIC | -0.16 | -0.17 | -0.18 | -0.24 | -0.28 | |
| Return on tangible assets | -0.13 | -0.15 | -0.16 | -0.16 | -0.24 | |
| Graham Net | 2.26 | 1.28 | 0.7 | 0.64 | 0 | |
| Working capital | 185.68M | 177.69M | 169.01M | 164.49M | 124.62M | |
| Tangible asset value | 116M | 85.09M | 57.34M | 54.54M | 16.77M | |
| Net current asset value | 97.03M | 57.47M | 50.75M | 48.77M | 11.1M | |
| Invested capital | 0.63 | 1.23 | 1.84 | 1.36 | 6.54 | |
| Average receivables | 4.87M | 9.02M | 8.46M | 4.76M | 4.04M | |
| Average payables | 4.59M | 5.4M | 3.38M | 2.46M | 3.31M | |
| Average inventory | 90.5K | 57K | 1.36M | 2.71M | 2.57M | |
| Days sales outstanding | 79.77 | 101.38 | 77.46 | 52.51 | 47.55 | |
| Days payables outstanding | 1.95K | 1.95K | 536.74 | 519.43 | 356 | |
| Days of inventory on hand | 23.73 | 16.17 | 623.47 | 541.19 | 214.59 | |
| Receivables turnover | 1.13 | 0.89 | 1.16 | 1.71 | 1.89 | |
| Payables turnover | 0.05 | 0.05 | 0.17 | 0.17 | 0.25 | |
| Inventory turnover | 3.79 | 5.57 | 0.14 | 0.17 | 0.42 | |
| ROE | -0.3 | -0.41 | -0.56 | -0.6 | -2.49 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
MRNS Frequently Asked Questions
What is Marinus Pharmaceuticals, Inc. stock symbol ?
Marinus Pharmaceuticals, Inc. is a US stock , located in Radnor of Pa and trading under the symbol MRNS
What is Marinus Pharmaceuticals, Inc. stock quote today ?
Marinus Pharmaceuticals, Inc. stock price is $1.44 today.
Is Marinus Pharmaceuticals, Inc. stock public?
Yes, Marinus Pharmaceuticals, Inc. is a publicly traded company.
Company Profile
- Volume Average 440.93K
- Market Capitalization 410.91M
- Employee 165
- CEO Dr. Scott N. Braunstein M.D.
- Headquarters Radnor,PA,US
- IPO Date 2014-07-31
-
Website
https://marinuspharma.com 
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
